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Scaling and Splitting:
New Approaches to
Health Insurance

I

How can we cut health care costs while expanding access to care?
✒ By Christopher T. Robertson and Keith A. Joiner

n the United States, cost-sharing in health insurance coverage has become the primary mechanism
for reducing insurance expenditures and, by extension, maintaining affordable coverage. Cost-sharing
involves patients making various out-of-pocket (OOP)
payments for their own health care aside from whatever the insurer pays.
As a patient’s spending on health care grows month by month
in any given year of coverage, she moves through three different
“zones” of insurance, from no insurance, to partial insurance, and
finally to full insurance. Looking at these zones individually:
Zone 1—No Insurance: An annual deductible gives the patient
complete responsibility for the first health expenditures in a year.
In other words, the patient has 100 percent “skin in the game”
for those expenditures. In common plans, the average annual
deductible is less than $1,000.
About one-quarter of American workers are in “high-deductible health plans with a savings option,” meaning that the insurance is paired with a tax-advantaged savings plan for medical
expenditures. The average deductible for these plans is a bit over
$2,000, though federal law allows them to be as high as $12,000
for families. High-deductible plans, as a percentage of plans
offered and of employees enrolled, have increased more than
five-fold over the last decade. Many employers are eliminating all
other options for their employees.
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Zone 2—Some Insurance: In this zone, patients share the burden
of health care consumption through copayments, coinsurance,
or reference pricing. A copayment is a flat fee paid at a doctor’s
office, hospital, or pharmacy, while coinsurance is a percentage
(typically about 18 percent) of the cost of the service or drug.
Under a “reference price,” an insurer pays a fixed amount for a
service and the beneficiary pays all charges above that amount.
These forms of cost-sharing are intended to decrease “moral
hazard,” in which patients consume more health care than is
efficient because they bear little of the cost. But these forms of
coverage can lead to “behavioral hazard,” in which services or
drugs of clear medical benefit are under-utilized because patients
shy away from the co-pay. Most consumers do not (or are not able
to) distinguish between care that is considered highly beneficial
and care that is of minimal benefit or even potentially harmful.
Zone 3—Full Insurance: Finally, there is a zone in which patients
have no “skin in the game” at all and insurance covers the full
cost of care. Most individual workers have cost-sharing burdens
capped at some amount less than $3,000 per year (or less than
$5,500 for family-coverage), after which all expenses become the
responsibility of the insurer. Although most plans included such
a cap already, it is now required by the 2010 Patient Protection
and Affordable Care Act (ACA).

Imagine an insured, Ms. Mildred Median, whose plan has a
$1,000 deductible, an 18 percent coinsurance burden, and a $3,000
cost-sharing maximum. Suppose that this year, she will spend tens
of thousands of dollars on a heart stent, chemotherapy drug, or
other high-cost care. After spending her $1,000 deductible, she
will be exposed to up to $2,000 more in costs ($3,000 cap minus
the $1,000 deductible). Given her 18 percent coinsurance rate,
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that $2,000 will be consumed after the next $11,111 in health care
expenses. Thus, Ms. Median has reached Zone 3, where she has
full insurance with no more skin in the game, after consuming
$12,111 in health expenses, $3,000 of which she paid out of pocket.
For Ms. Median, the cap is a good thing. If she also earns a
median family income of about $51,000, her health care expenses
will have consumed 6 percent of her pre-tax income. Depending
on her other obligations and the
amount she has put into savings,
she may not have been able to bear
more risk. In this sense, the Zone
3 cap is doing exactly what it was
designed to do.
Such a cap is anathema for cost
control, however. The vast majority
of health spending is consumed by
a minority of individuals who each
account for tens of thousands of
dollars of health care consumption in a given year. (This is the
familiar “80-20 rule” for health
care costs—20 percent of the population consumes 80 percent of
the care.) Thus, the cap on outof-pocket spending deprives the
insurer of its primary cost-control
mechanism at precisely the point
where the expenditure decisions
are most effective in controlling
aggregate costs.
The two goals for a rational
health insurance policy are in
inherent tension: too high a cap
hinders risk protection; too low a
cap hinders cost-control.
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Scaling

Individuals have radically different
abilities to bear risk. For instance,
those in the top quintile of the
U.S. household income distribution are paid five times more than
those in the bottom quintile. Yet,
within a given health plan, they
all have the same cost-sharing burdens, given the prototypic process
for pricing insurance premiums
and cost-sharing obligations.
Accordingly, the cap will be too
high for some beneficiaries, making them “underinsured” because
it undermines the risk-protecting
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and access-guaranteeing purposes of health insurance. The same
cap will be too low for other beneficiaries, removing the price
signal sooner than necessary and making them “overinsured.”
These individuals no longer have any skin in the game, and thus
they can spend without any market discipline. Prior empirical
research shows that wealthy individuals can accept greater risk
without adverse consequences for their health.
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The language of taxation may provide normative traction as
to the fair distribution of health care expenses between individuals and their collective insurance pools. A “progressive” tax is
typically paid as a percentage of adjusted income, with several
tiers of increasingly higher percentages. Such a policy is sensible
to the extent that income past a certain level is more disposable
than income at the lower levels, which must be allocated to basic
human needs. A “flat rate” or “proportional” tax is one where
everyone pays the same percentage of income. Although rare today
in overt forms, a “head” tax is one where each individual pays the
same dollar-amount regardless of wealth or income. The head tax
is thought to be objectionably regressive.
Our current system, in which each employee faces the same
amount of health care costs in order to get the full insurance of
Zone 3, is analogous to a head tax. It is regressive in the sense
that lower-paid workers must pay a larger percentage of their
incomes than higher-paid workers. Coupled with the fact that
health insurance premiums are paid with pre-tax dollars, lowerincome workers (in lower tax brackets) are effectively subsidizing
insurance costs for those with higher incomes. For lower-income
workers, choosing high-deductible plans with lower premiums
in order to afford insurance does not solve this dilemma, and in
many ways exacerbates it.
In contrast, the optimal insurance policy will be one that scales
the cost-sharing burdens for each beneficiary to his or her ability
to bear that uninsured risk. Scaled cost-sharing (SCS) is feasible in
a world where employers pay wages and provide health insurance;
the two data points need only be linked together. Even outside the
employer-sponsored health insurance market, it is relatively easy
to get wage information. Those same data are used to calculate
premium subsidies in the individual market. Although scholars
have periodically recognized the concept of scaling, it has not yet
achieved the sustained attention and prominence it deserves in
scholarly and policy debates.
One imperfect but feasible mechanism for such tailoring would
look like the following: Instead of exposing all beneficiaries to the
same fixed-dollar amount of uninsured risk per year, the insurer
would expose all beneficiaries to the same percent of their wages
as the uninsured risk. For example, we could use as a baseline a
common cost-sharing profile that includes a $3,000 cost-sharing
cap, and apply it to a median American worker with a $50,000
income. This median worker with an average plan faces a 6 percent
cost-sharing ratio. We could then apply that same 6 percent ratio
across the board, scaling the absolute cost-sharing amount upward
or downward with each person’s income. In this arrangement, each
beneficiary gets roughly the protection from risk that she needs,
while also continuing to have as much skin in the game as she can
handle. Such an implementation would be analogous to a flat-rate
tax, but more progressive options may be worthwhile to consider.
This is not a zero-sum reform that simply redistributes risk from
the poor to the wealthy. Instead, because the wealthy are better able
to bear that risk, SCS should also appeal to rational employers

who seek to maximize shareholder value while providing employee
insurance. Because the distribution of American workers’ incomes
is concentrated in favor of the highly compensated, proportional
income-scaling will also be asymmetric. One of us, Christopher
Robertson, has estimated that a 6 percent scaling would add four
times more cost-sharing than it removes, thereby significantly
reducing the aggregate burden of insurance premiums.
SCS is also unique among “consumer-directed health insurance” reforms in that its increase of the catastrophic caps for half
of the population will affect high-cost health care, which accounts
for the bulk of overall spending. Thus, SCS could significantly
reduce insurance outlays in this second respect. Moreover, SCS
promises to deliver better health outcomes and enhanced worker
productivity for each dollar spent on health insurance. For these
reasons, SCS may allow a greater bargaining surplus between
workers and shareholders.
There are intellectual precedents for SCS. In the market for
goods and services, sellers often use differential pricing (e.g., Acura
and Honda) to sell to consumers with a range of willingness to pay.
This strategy can increase access to goods and improve profits for
the seller, enhancing overall welfare. Several European countries have
adopted income scaling for speeding tickets in an effort to make the
deterrent effect proportionate across heterogeneous drivers.
For health insurance in particular, it is important to distinguish the proposal for scaling cost-sharing (out-of-pocket
payments by insured individuals for their medical care) from
the scaling of insurance premiums (monthly payments required
in order to maintain an active insurance plan). While scaling of
costs has received only minor consideration by economists, many
scholars have recommended the scaling of premiums, which
already appears in some federal programs and in benefit plans for
about 10 percent of large employers. While premium scaling may
serve fairness goals, it does almost nothing on its own to solve
the problems of underinsurance and overinsurance.
Why isn’t scaling already happening? / One may ask why employers
have not widely adopted wage-scaled cost-sharing in the insurance plans they offer. There are five potential sources for this
apparent market failure.
First, one might wonder why a choice-based system, in which
workers would select their own cost-sharing profiles and pay
insurance premiums accordingly, has not emerged. Car and
home insurance often already operate in this fashion. The longstanding practice of employers contributing to health insurance
premiums (even though the costs are ultimately borne by the
employee) and the legal limits on individual-rating of premiums
present obstacles to this approach. In this domain, choice also
presents problems of adverse selection by allowing beneficiaries
to exploit their private information, which undermines the riskpooling function of insurance. More generally, a choice-based
mechanism could be compromised by the severe cognitive limits
that individuals face when making such complex decisions about
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risk. As a result, greater intervention by employers and regulators
may be sensible in this domain; they could move toward scaling
while holding constant the lack of choice that exists in employersponsored plans today. Nonetheless, as an intermediate step,
employers could implement scaling as a default rule.
A second significant obstacle is that well-intentioned caps on
cost-sharing in the ACA limit the potential application of SCS.
This is an unfortunate limitation in the ACA, but the executive
branch could facilitate reforms through thoughtful interpretations of the law and the exercise of discretion in enforcement.
Congress could also fix this flaw. Even without such reforms,
employers have considerable discretion to use scaling beneath
those statutory caps.
Third, there may be an agency problem. Managers responsible
for designing the firm’s insurance policy are paid more than the
median worker, which may cause them to reject SCS even if it
would improve profits for the shareholders. There is a related
collective action problem in the market for talented workers.
Employers are hesitant to be the first to
impose higher cost-sharing burdens on
their highest-paid workers, lest they lose
them. Fundamentally, these problems
are caused by the tax code, which creates
a distortion in favor of health spending
through insurance. This distortion is especially pronounced for high-paid workers.
Fourth, there will be difficult questions
in the transition, as changes in the actuarial value of insurance for any particular
worker could be perceived as changing the
value of the worker’s overall compensation package, which thus
may call for untenable adjustments on the salary side (the compensating differential). However, the overall cost of health insurance should decrease with SCS—assuming that premiums would
decline in conjunction with higher cost-sharing obligations for
higher-paid workers and the overall higher amount of cost-sharing
because of the skew in wages. This efficiency creates a bargaining
surplus that allows a win–win redistribution between classes of
workers and shareholders. Additionally, for higher-paid workers
with health savings accounts and similar tax-preferred vehicles, significantly higher OOP unreimbursed expenses would be partially
offset by the income tax deductions associated with such expenses.
Fifth, there may be misperceptions that current federal law
prohibits this sort of “discrimination” by salary levels. One of
us, Christopher Robertson, has shown elsewhere that the law
is actually permissive. Indeed, it arguably obliges employers to
use scaling in order to allow lower-paid workers to get the full
benefit of their health insurance without hiding tax-free compensation for top workers in the form of unnecessary insurance.
Thanks to an expansion of this unenforced rule in the ACA, the
IRS now has a legal mechanism to counteract the distortion of
the tax preference. It need only clarify its regulations to require
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scaled cost-sharing. Lower-paid workers may also have options
for litigation. Accordingly, congressional action is unnecessary
for this landmark reform. The Internal Revenue Service, or individual litigants, could nudge employers toward scaling, helping
to achieve health insurance’s goals and reduce its distortive effects
on consumption. Scaled cost-sharing is smarter insurance.
Splitting

As we have seen, the fundamental problem for cost-sharing is that
the cost of treatment can be disproportionate to patients’ ability to
pay even a portion thereof. That is why we limit cost-sharing exposure. But our proposal, so far, also defeats the cost-containment
virtue of cost-sharing by giving patients carte blanche when they
make the most costly consumption decisions. Even with scaling,
caps on OOP will remain. But we have a way to address this problem while retaining consumer choice in treatment.
It is remarkable that insurance currently provides only an
“in-kind” benefit, paid to the provider rather than the beneficiary.

The “split benefit” would divide the health insurance
payment between the provider and the patient, rather
than simply paying it to the provider. This would
guarantee health care access and patient choice.

Alternatively, for expensive treatments (costing, say, $100,000), the
insurer could consider satisfying its coverage obligation by paying
a portion (say, $10,000) directly to the patient. The patient then
decides whether to spend that portion on the treatment. If so, the
insurer pays the balance ($90,000) to the provider, thereby insuring
access. If the patient instead declines the care, he or she can save
or spend the money on anything else. The insurer saves the balance ($90,000). We call this a “split benefit” because it divides the
health insurance benefit payment between the provider and the
patient, rather than simply paying it to the provider as is done now.
Strikingly, the split benefit guarantees health care access and
patient choice precisely to the same extent as current in-kind
insurance benefits. For this reason, the split benefit is consistent
with current insurance contracts and regulations because it does
not change coverage or the size of the benefit. That feature makes
the split benefit practicable, unlike many other theoretical solutions. The split benefit can be used alongside other insurance
mechanisms, including traditional cost-sharing (scaled or not),
exclusions, and fail-first policies.
The split benefit creates new options for the patient. Because it
is fungible, the split benefit creates an opportunity cost, causing
some patients to decline the expensive treatment in lieu of medical
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and nonmedical alternatives that they value more highly. In this
way, once the split is paid, it functions exactly the same way as a
traditional cost-sharing burden. It is an out-of-pocket payment.
The insurer can exercise the split benefit as a unilateral option
whenever it is most likely to save money. Insurers will find the
split benefit most useful for procedures (whether drugs, devices,
surgeries, or diagnostics) that meet four criteria:
The insurer must cover the procedure.
■■ The price of the procedure is disproportionate to the
patient’s wealth.
■■ The patient would otherwise be likely to consume the treatment.
■■ The procedure is not proven to reduce health care expenditures on net.
■■

The fourth criterion reflects the rational interests of any insurer.
It is folly to use the split benefit or any other mechanism to try
to dissuade patients from consuming health care that is actually
efficient from a financial point of view.
Even with those limitations, the split benefit proposal covers a
broad swath of American health care. A 2006 study found that 21
percent of all prescriptions written in the United States are for offlabel uses and that most of those had little or no scientific support.
Many of the most expensive treatments (such as heart stents) are
proven effective for some patients, but are used widely for others.
Estimates from many sources and using a variety of approaches
have concluded that approximately one-third of all medical expenditures in the United States are either wasteful or harmful.
Recent initiatives to identify and highlight a list of such interventions in various medical specialties are a step in the right direction, but are unlikely to have a substantial effect on costs in the
short or even intermediate term. First, a report from the Institute
of Medicine suggested that 17 years are needed before a large
majority of physicians adopt new practice recommendations. Second, the interventions identified are few in number. Third, those
recommendations come from the provider community, which (at
least in the current fee-for-service payment model) is incentivized
to maintain the options for reimbursement at nearly a steady
state. This much larger zone of unproven, low-value health care
would be a prime target for the split benefit, although it would
be unlikely to be driven from the provider side.
Whether the split benefit should be extended to other health
care that is costly on net, but is proven to have high value for at
least some patients, is an open question. One concern is that,
given the churn in the health insurance market, insurers may
be biased against health care consumption and thus may use
the split benefit and other cost-control devices too often on the
margins. We tentatively suggest that the split benefit is warranted
wherever and to the same extent that traditional cost-sharing is
appropriate. In fact, it is a form of cost-sharing that simply solves
a wealth problem.
The insurer also has the discretion to select what level of split

is optimal for each patient. The optimal size of the split-benefit
payment is an empirical question, one that is likely context-dependent. There will presumably be diminishing marginal returns,
such that moving from a 1 percent to a 10 percent split may yield
a very large reduction in the rate of consumption, but the equally
costly step of moving from a 10 percent split to a 19 percent split
may yield little additional benefit.
Testing the concept /

To investigate those empirical questions,
we fielded a randomized vignette-based experiment in which we
exposed a diverse group of 1,800 respondents to stories asking
them to imagine a future decision about whether to consume
a particular expensive, unproven treatment. We manipulated
whether a split-benefit payment was offered, the amount of the
split ($5,000 or $15,000), and the type of split offered. We conceived three such types:
payment via bank check that the patient receives in advance
of the health care decision, and simply keeps if he declines
care
■■ a rebate offering payment after the decision is made, conditional on declining care
■■ another prepayment, but paid into an account with fungibility limited to other health expenses, similar to a health
savings account
■■

We found that offering a split benefit substantially reduced the
intent to consume. It did not much matter how large the payment was or its form. We also asked respondents whether they
viewed the insurer as treating them fairly, and they responded
very positively. They also supported the idea of a split benefit
being used to save costs in Medicare, and amazingly we detected
no political polarization on that point.
Our study suggests that the split benefit could be useful as
a way for public and private insurers to reduce consumption of
the high-cost, low-value care that drives much of health spending. And they can do so without reducing access or infringing on
patient choice. Indeed, the data suggest that insurers have flexibility as to how they pay a split, in the amount and type. Those
paying a split will be perceived fairly; after all, the only effect of a
split is to increase the patient’s wealth and options.
Weighing objections / Admittedly, the split benefit may create a
perverse incentive for individuals to seek prescriptions for treatments they otherwise may not have consumed anyway (a problem of “false demand”). To some degree, insurers can observe and
police these dynamics. Insurers should not use the split benefit
for ailments that are easy to fake or where the diagnosis is highly
subjective. For example, nonspecific back pain may be one such
diagnosis that could be opportunistic for a higher percentage of
patients than other diagnoses, such as breast cancer. Still, if small
split-benefit payments significantly reduce consumption, there
will be some tolerance for the stimulation of false demand. If a
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$5,000 payment prevents consumption of a $100,000 treatment,
as our experiment suggests, the insurer could tolerate a dozen
or more false demand payments while still saving money on net.
One might object that the split-benefit payment seems coercive,
potentially pushing patients away from consuming health care.
To the contrary, the entire insurance relationship on net, even
including a split-benefit payment, still induces patients toward
consuming health care. The insurer tells the patient that he or
she can spend the money on anything, but if the patient wants
to consume health care, then the insurer will provide a ninefold match of the patient’s money (assuming a 10 percent split).
Merely allowing the patient to decide how she wants to spend
one-tenth of her insurance benefit does not constitute coercion.
Still, there may be situations where the patient cannot decide
whether to consume a treatment, and where someone else—such
as a parent or next of kin—decides on the patient’s behalf. The
split-benefit proposal may create a conflict of interest if that
substituted decisionmaker receives the benefit of the cash payment (either through expropriation or inheritance), while the
patient receives the benefit (if any) of the treatment. It may be
best to limit the split-benefit program to only those situations
where the patient is competent to make treatment decisions. Still,
traditional cost-sharing obligations already impose these sorts
of dilemmas on substituted decisionmakers, who would rather
keep the money. Even worse, traditional cost-sharing obligations,
unlike the split benefit, may be so onerous that they deny access
to the expensive care altogether.
The poorest patients also present a particular concern. The poor
patient’s alternative consumption choices for food or housing are
more pressing than those of the median patient. This makes the
poor patient more likely to decline care in order to pursue those
alternatives. Insurers could scale split-benefit payments according
to patient wealth (giving the poor smaller splits), but that may
appear unfair. With same-size splits, the benefits of a fungible payment will be greatest for the poor precisely because those alternative
consumption options—such as food or housing—will actually be
better for the poor patient than expensive health care. Even if we
focused exclusively on health outcomes, evidence suggests that
investments in housing, diet, and education may prove more effective than investments in expensive medical interventions. If the
choice is hard, it is because the alternatives are attractive.
A related objection would invoke the “specialness” of health.
One might argue, in the words of economist and philosopher
Amartya Sen, that “health is among the most important conditions
of human life and a critically significant constituent of human
capabilities which we have reason to value.” Thus, it may seem
perverse for the split-benefit policy to facilitate patients trading
health care in favor of other goods such as housing or even jewelry.
This critique does not bear scrutiny. People buy insurance to
ensure future access to care that they otherwise could not afford.
Ex ante, consumers need not know whether they will actually
want to consume a given drug for a given disease that they may
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someday suffer. But rational consumers want the option to
consume such treatment when they become better informed by
their actual experience of the situation. After all, patients want
health, not health care. Interventions are not valuable per se,
but only because they may increase well-being. Ex post, having
secured the option, a rational consumer may nonetheless prefer
to spend that benefit on other goods that they judge to have a
more substantial effect on their well-being. The split benefit is
perfectly congruent with the option-buying purpose of insurance.
It has the side benefits of increasing patient wealth and reducing
insurance costs along the way. On the aggregate, a split-benefit
reform may correct the systematic bias in our economy toward
low-value, high-cost health care.
Arguably, the split benefit is a better solution than traditional
cost-sharing or rationing by insurers or physicians, which reduce
access to care. If a physician refuses to write a prescription because
of cost, if an insurer refuses to cover such a prescription, or if an
onerous cost-share exceeds a patient’s ability to pay, the health
care system has denied the patient the choice. In contrast, the split
benefit keeps the decision in the hands of the patient. The proposal
serves patients’ autonomy by giving them additional options.

Conclusion

We have presented two reforms to health insurance, which could
be applied in the employer-sponsored insurance market, the individual exchanges, or in Medicare. There are, of course, other ways to
control health care costs—including the centralized rationing policies that are used more overtly abroad and the move toward partial
or full risk-adjusted capitation. However, cost-sharing is attractive
in the current fee-for-service payment environment because it leaves
the choices in the hands of patients themselves. Scaling and splitting are simply ways of making cost-sharing work better.
We suggest that policymakers and insurance designers use a
combination of scaling and splitting. First, adjust cost-sharing
burdens according to wealth or income, so that patients will be
required to pay as much as they can bear from their own pockets.
Then, when patients’ health care consumption crosses beyond
the scaled cap, begin using the split benefit—paying them the
wealth necessary to keep their skin in the game. In this way, we
can achieve the purposes of insurance—protection from risk and
guaranteed access to care—while also maintaining cost-control
through the market-mechanism of consumer choice.
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